

Use of Allogeneic Tumor Vaccines Expressing
the $\alpha(1,3)$ Galactosyltransferase Gene

Protocol 550: Breast Cancer

Protocol 552: Lung Cancer

December 6, 2002

Participating Investigators

- *National Cancer Institute*

- John Morris, M.D. (PI 552)
- John Janik, M.D.

- *Stoddard Cancer Research Institute, Iowa Methodist Medical Center*

- Roscoe Morton, M.D. (PI 550)
- Charles Link, M.D.
- Tatiana Seregina, Ph.D.
- Thomas Buroker, M.D.
- Robert Unfer, Ph.D.
- Gabriela Rossi, Ph.D.

- *NewLink Genetic Consortium (Study Sponsor)*

- Nicholas Vahanian, M.D.
- Jay Ramsey, M.D., Ph.D.


Xenotransplantation of Murine HSVtk Vector Producer Cells (VPC) into Women with Ovarian Cancer

- Failed chemotherapy with a platinum agent and paclitaxel
- ECOG performance status ≤ 2
- Patients received up to 7 billion murine cells by IP infusion
- No significant gene transfer, but some clinical responses including a CR by CT scan

Experimental and Clinical Data to Support Hyperacute Cancer Vaccine Approach


Patient	Age/ Stage	Tumor	Dose level	Dose (VPC)	Gene Transfer Observed	Result	Comments
1	64 IIIC	Ovarian	1	56 million	Not Tested	Partial Response	Local tumor necrosis
2	47 IIIC	Ovarian	1	57 million	No	Mixed response	Resolved ascites before GCV Rx
3	59 IIIC	Ovarian	1	56 million	No	Progressive Disease	Deceased 15 months after treatment
4	51 IIIC	Ovarian	2	680 million	Yes	Progressive Disease	Deceased 5 months after treatment
5	62 IIIC	Ovarian	2	700 million	Not Tested	Progressive Disease	Deceased 6 months after treatment
6	66 IIIC	Fallopian	2	840 million	Yes	Minimal Response	Deceased 8 months after treatment
7	73 IV	Ovarian	3	7 billion	No	Progressive Disease	Receiving chemotherapy
8	60 IIIC	Ovarian	3	6.3 billion	No	Stable	CT scan without disease CA125 decreased 70%
9	63 IIIC	Ovarian	3	6.2 billion	Yes	Progressive Disease	Deceased 3 months after treatment

Ovarian Cancer Patients Treated with Murine VPC Develop Increased Anti- α Gal Ab Titers



Can the Hyperacute Rejection Phenomena
Increase Anti-tumor Response ?

Xenotransplantation: problem of hyperacute rejection of a transplant



Humans, apes, and Old /world primates lack $\alpha(1,3)\text{GT}$

Humans have high titer anti- αgal Ab

Anti- αgal antibodies are responsible for hyperacute rejection of xenotransplants

α GT expression Confers Susceptibility to Lysis by Normal Human Serum


- Murine VPC and retroviral vectors are lysed by NHS secondary to anti- α gal Ab binding and activation of complement
- Human cancer cells transduced with $\alpha(1,3)$ GT gene express α gal and are lysed by NHS

	α gal Expression by FACS	Human Serum	Human Serum +sCR1	Human Serum Heat Inactivated
Cell Line		%Viable	% Viable	% Viable
A375	-	98.7	not done	96.9
A375aG.7	+	2.6	92	93.9
A375aG.8	+	11.1	91.6	95.5
A375aG.11	-	96.2	not done	not done


Preclinical Data: α GT KO Mouse Model

- The recently generated α GT "knock-out" (KO) mouse provides a small animal model to study the *in vivo* immune response against α gal epitopes on tumor cell lines.
- α GT-KO mice can be immunized to stimulate a high titer of anti- α gal antibody.


Killing of Murine MC38 Colon Cancer Cells With Normal Human Serum




In vivo effect of tumor cells expressing α gal in a murine tumor model




Challenge of Immunized Mice with α gal Positive MC38 Tumors




Survival of Immunized KO Mice Following B16 Tumor Challenge




Immunity to αGal^+ B16 Cells Rejects Challenge With αGal^- B16 Cells



Protected Mice Develop Melanoma Specific CTL Responsive to α gal Negative B16



In vivo anti-tumor vaccination effects using tumor cells expressing α -gal



T mor-free Survival at day 26 (12/04/02)


12/20, $p < 0.05$

4/12, $p > 0.05$


4/14, $p > 0.05$

0/10

Hyperacute® Cancer Vaccine Using Gene Transfer



Human Breast Cancer Cells Expressing α GT Stained With Anti- α gal Ab (HAB-1 and HAB-2)



Toxicity Study for the Allogeneic Breast Cancer Vaccine

Animal treatments

α GT KO mice
b/b Haplotype

1



IP



Rabbit Red Blood Cells (RRBC)

EMT-6 cell vaccine
Allogeneic, SC (d/d haplotype)

Test Groups

2 weeks

4 weeks

6 weeks

6 months

2



IP



Rabbit Red Blood Cells (RRBC)

RRBC Group

3







Naïve group

Absence of Immediate Hypersensitivity After Vaccination With Allogeneic Irradiated Breast Cancer Cells



24 hr after vaccination

Hematologic Results



Animal Model Toxicity Study Summary:


α GT KO mice (n=15) were studied after receiving EMT-6 allogeneic murine breast cancer cells (α GT⁺)

- No observed behavioral or motor abnormalities in mice
- No signs of immediate toxicity in the skin
- No significant hematologic alterations (n=15 vaccinated animals)
- Increase in Eosinophils, 2 weeks after vaccination (similar to observation in ovarian clinical trial patient receiving VPC)
- No pathology of major organ systems or mammary glands.

Toxicity in Phase I Trial of Murine VPC in Women With Ovarian Cancer

- Up to 7 billion α gal positive murine VPC administered
- No grade 3 or 4 toxicity observed
- Fever < 101.5 in most patients for 4 to 5 days
- Anorexia
- Mild to moderate nausea with or without vomiting
- Abdominal pain (mild to moderate) for up to 7 days

Lung Cancer




- U.S: 169,000 new cases and 155,000 deaths in 2002
- Leading cause of cancer death
- Surpassed breast as leading cause of cancer death in women in 1987
- ~15% of smokers develop lung cancer
- 5-year survival (all cases):
 - 1960- 10%
 - 2000- 13-15%

Advanced NSCLC

- 70% patients present with advanced stage (III/IV) disease
- Treated with chemotherapy± radiation
- 5-years survival:
 - Stage III- 10-19%
 - Stage IV- <2%

Chemotherapy in Advanced NSCLC



Study Objectives

- Phase I: Determine the side-effects, DLT and MTD of the HyperAcute™ Lung Cancer (HAL) Cell vaccine in patients with advanced or relapsed NSCLC
- Phase II: Determine the response of advanced or relapsed NSCLC to the HAL Cell vaccine
- To assess the immunological response of patients with advanced or relapsed NSCLC to the HAL Cell vaccine

Assessments

- Toxicity will be assessed using NCI CTC grading of symptoms, physical findings and laboratory tests
- Tumor response will be determined using NCI RECIST criteria for tumor measurements
- Determination of serum anti-a-gal titers, HAL cell stimulation of IFN γ /IL-5 production by PBMC, and demonstration of CTL activity before and after completion of vaccination


Eligibility Criteria

- NSCLC
- AJCC Stage IV, progressive or recurrent NSCLC
- ECOG PS ≤ 2
- Life expectancy ≥ 3 months
- Measurable disease
- Adequate organ function
- Up to 2 prior therapies
- Informed consent

Exclusion Criteria

- Age < 18 yrs.
- CNS involvement
- Hypercalcemia
- HIV, HCV or chronic active HBV
- Pregnant or nursing women
- Organ transplant or immunosuppressive therapy
- Autoimmune disease
- Active serious infection
- Other serious medical or psychiatric disease
- Known allergy to a(1,3)GT or vaccine cell lines

HyperAcute™ Lung Cancer Vaccine. Treatment Plan



↓ Immunological evaluation

↓ HyperAcute Lung Cancer Cell vaccine (HAL) i.d.

HyperAcute™ Cell Vaccine NSCLC Trial Phase I Dose Escalation

Cohort	No. Pts.*	HAL Vaccine Cells (Total No. cells)
I	3	3×10^6
II	3	1×10^7
III	3	3×10^7
IV	3	1×10^8

*Cohort expanded to 6 Pts. if DLT seen.

Phase I/II Study of Antitumor Vaccination Using $\alpha(1,3)$ GT-Expressing Allogenic Tumor Cells in Patients with Breast Cancer

- **ACS 2002 Breast Cancer Incidence 203,500 women with 39,600 deaths**
- **Tumor vaccine: allogeneic cells transfected by with the murine $\alpha(1,3)$ GT gene results in epitopes (α gal) glycoproteins and glycolipids.**

Objectives

- Dose Limiting Toxicity (DLT)
- Maximum Tolerated Dose (MTD)
- Assess tumor response rate
- Assess immunologic response to antitumor vaccines with $\alpha(1,3)$ GT

Inclusion Criteria

- Histological diagnosis of recurrent breast cancer
- ECOG Performance Status ≤ 2
- Good end organ function
- Life expectancy > 3 months
- Measurable or evaluable disease
- Failed one salvage regimen for stage IV disease
- Ability to provide Informed Consent

Exclusion Criteria

- Age < 18 yrs.
- CNS involvement
- Hypercalcemia
- HIV, HCV or chronic active HBV
- Pregnant or nursing women
- Organ transplant or immunosuppressive therapy
- Autoimmune disease
- Active serious infection
- Other serious medical or psychiatric disease
- Known allergy to $\alpha(1,3)$ GT or vaccine cell lines

On-Study Testing

- CBC and metabolic profile
- CH50, ANA, RA, ESR
- Pregnancy test: β -HCG Flow cytometry: T & B cells, Tac (IL-2R α), CD3, CD4, CD7, CD8, CD20, CD25
- Anti- α -gal antibodies
- Imaging studies of disease site(s)
- Skin test: tetanus, mumps, PPD-intermediate, candida albicans

Treatment

- HAB vaccine cells: intradermal injection on days 1, 29, 57, and 85
- Phase I: 3 patients at 3.0×10^6
3 patients at 1.0×10^7
3 patients at 3.0×10^7
3 patients at 1.0×10^8
- Phase II: 32 patients at the maximum tolerated dose (MTD)

Correlative Studies

- Anti- α -gal antibody titers
- Cytolytic T-lymphocytes (CTL)
- Cytokine Assays: Interleukin-5 (IL-5), IL-10, and gamma interferon (IFN- γ)

Measurement of Effect

- RECIST Criteria for Solid Tumors
- Confirmation of Response at 4 weeks
- CT-Scan preferred for measurement